Report : Asia Pacific Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology (Molecular Diagnostics {Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, Microarrays}, Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, and Microbiology), Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)

At 9.6% CAGR, the Asia Pacific Sepsis Diagnostics Market is speculated to be worth US$ 249.70 million by 2028, says Business Market Insights           

According to Business Market Insights’ research, the APAC sepsis diagnostics market was valued at US$ 131.79 million in 2021 and is expected to reach US$ 249.70 million by 2028, registering an annual growth rate of 9.6% from 2021 to 2028. High frequency of sepsis due to increasing nosocomial infections and expansion in demand for rapid diagnostic tests leading to increasing product launches are the critical factors attributed to the market expansion.               

Most of the diagnostic tests for sepsis are time-consuming and take up to 72 hours to provide results. In the era of molecular diagnosis for every kind of disease, the demand for rapid diagnostic tests for sepsis is rising. To fulfill this rising demand, many key players operating in the industry put efforts into developing innovative rapid diagnostic tests for sepsis. Moreover, the key players developed cost-effective diagnostic tests to overcome all the challenges associated with sepsis diagnosis. For instance, Inflammatix, a pioneering molecular diagnostics company, announced the publication of a health economic model that shows the use of the company's HostDxTM Sepsis test is cost-effective as compare to standard methods. The test was performed on patients suspected of acute respiratory tract infections (ARTI) in Emergency Departments. The study was published in April 2020 in The Journal of Health Economics and Outcomes Research. The model informed hospital clinicians of the potential clinical and economic benefits of widespread adoption of the HostDx Sepsis test. The DxH 690T reported accurate results and improved turnaround time by reducing procedural steps and manual touchpoints, making it an ideal solution to help relieve some of sepsis disease burden. Thus, the rising in demand of rapid diagnostics test led to product launches and are expected to drive the sepsis diagnostics market during the forecast period. This is expected to drive the market during the forecast period.

On the contrary, loss of skilled professionals hurdles the growth of APAC sepsis diagnostics market. 

Based on product, the APAC sepsis diagnostics market is divided into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held 43.7% market share in 2021, amassing US$ 57.53 million. It is projected to garner US$ 108.19 million by 2028 to expand at 9.4% CAGR during 2021–2028.    

Based on technology, the APAC sepsis diagnostics market is categorized into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held 44.3% market share in 2021, amassing US$ 58.39 million. It is projected to garner US$ 108.74 million by 2028 to expand at 9.3% CAGR during 2021–2028.  Further molecular diagnostics flow cytometry segment is further categorized into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, microarrays.

Based on Method, the APAC sepsis diagnostics market is categorized into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held 66.4% market share in 2021, amassing US$ 87.51 million. It is projected to garner US$ 163.94 million by 2028 to expand at 9.4% CAGR during 2021–2028 

Based on test type, the APAC sepsis diagnostics market is divided into point-of-care tests and laboratory tests. The laboratory tests segment held 84.6% market share in 2021, amassing US$ 111.49 million. It is projected to garner US$ 210.34 million by 2028 to expand at 9.5% CAGR during 2021–2028 

Based on pathogen, the APAC sepsis diagnostics market is divided into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held 79.6% market share in 2021, amassing US$ 104.91 million. It is projected to garner US$ 201.64 million by 2028 to expand at 9.8% CAGR during 2021–2028 

Based on end user, the APAC sepsis diagnostics market is divided into hospitals, pathology and reference laboratories, and others. The hospitals segment held 47.8% market share in 2021, amassing US$ 63.04 million. It is projected to garner US$ 120.30 million by 2028 to expand at 9.7% CAGR during 2021–2028 

Based on country, the APAC sepsis diagnostics market has been categorised into the Australia, China, India, Japan, South Korea, and Rest of APAC.  Our regional analysis states that China captured 35.9% market share in 2021. It was assessed at US$ 47.35 million in 2021 and is likely to hit US$ 90.41 million by 2028, exhibiting a CAGR of 9.7% during the forecast period.            

Key players dominating the APAC sepsis diagnostics market are Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; and T2 Biosystems, Inc. among others.

  • In Mar 2020, Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte RAPID.
  • In April 2019, BD Unveils Platelet Quality Control Media to Help Reduce the Incidence of Sepsis.

Download Free PDF Brochure